OneMedNet Enters $1.5 Billion Healthcare Data Annotation Sector Through MedCase
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 24 2025
0mins
Should l Buy ONMD?
Source: Newsfilter
Strategic Partnership Announcement: OneMedNet Corporation has formed a strategic partnership with Medcase to enhance its position in the healthcare AI ecosystem, focusing on medical data annotation and creating new revenue channels.
Market Growth Potential: The healthcare data annotation market is projected to grow from $1.5 billion in 2025 to $2.8 billion by 2030, driven by increasing demand for specialized, regulatory-compliant data in AI model development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ONMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ONMD
About ONMD
OneMedNet Corporation is a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data (RWD), through its OneMedNet iRWD solution. The Company provides solutions within the clinical image archives of healthcare providers. It de-identifies, searches, and curates a data archive locally, bringing a wealth of internal and third-party research opportunities to providers. By leveraging this extensive federated provider network, together with technology and in-house clinical expertise, the Company meets the rigorous RWD life science requirements. OneMedNet iRWD offers advanced technology, clinical expert curation, and service. Medical imaging and associated clinical data are indexed at each network site using artificial intelligence (AI)/ machine learning (ML) technology. This includes EHR, radiology, cardiology, lab, path, and others. In addition to its customized data packages, it also offers regulatory-grade, pre-packaged imaging RWD sets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rapid Growth in Cardiac AI Diagnostics Market
- Market Surge: The global medical imaging market reached $45.5 billion in 2026, indicating a significant shift towards AI-native precision, particularly due to the rising demand for heart monitoring in cancer treatments.
- Rise of Cardiac AI Diagnostics: The cardiac AI diagnostics sector hit $2.22 billion in 2026, driven by the urgent need for continuous imaging to monitor heart dysfunction, enhancing the company's competitive edge in the medical technology market.
- Strategic Partnership Enhances Value: Ventripoint's collaboration with Summit Sciences to develop ROI models illustrates how hospitals can achieve cost savings through technological improvements, further solidifying its market position in cardiac care.
- Executive Appointment Fuels Growth: The appointment of David Swetlow as CFO, with extensive experience in medical technology, is expected to accelerate market adoption and revenue growth, driving the execution of the company's commercial strategy.
See More
Rapid Growth in Cardiac AI Diagnostics Market
- Market Size Surge: The global medical imaging market reached $45.5 billion in 2026, indicating a significant shift towards AI-driven precision, with the cardiac AI diagnostics sector hitting $2.22 billion, reflecting a critical demand for continuous imaging.
- Technological Innovation: VentriPoint Diagnostics is transforming standard 2D ultrasound images into MRI-level 3D heart models, significantly reducing costs and complexity, which is expected to drive rapid growth in its subscription business.
- Surge in Investment Demand: The company recently doubled its private placement from $500,000 to $1 million, with funds allocated for commercialization and market expansion, showcasing strong investor confidence in its technology and market potential.
- Strategic Partnership: VentriPoint's collaboration with Summit Sciences to develop ROI models aims to demonstrate the economic value of its technology to hospitals, further solidifying its market position in medical imaging.
See More
OneMedNet (ONMD) Aids mlHealth in FDA Approval of AI BrainCT Software
- FDA Approval Milestone: OneMedNet partnered with mlHealth 360 to secure FDA clearance for Scaida BrainCT-ICH, an AI software that detects intracranial hemorrhage from head CT scans in approximately 5.97 seconds, significantly enhancing clinical decision-making in acute care.
- Critical Data Support: OneMedNet's regulatory-grade Real-World Data, encompassing electronic medical records, diagnostic imaging, and clinical reports, played a pivotal role in model development, validation, and regulatory submission, underscoring the importance of high-quality data in accelerating innovation.
- Market Performance Review: Over the past year, ONMD's stock traded between $0.30 and $4.22, with a nearly 7% increase to $0.92, reflecting market recognition of its innovative capabilities.
- CEO Insights: OneMedNet's CEO Aaron Green stated that seeing the company's Real-World Data directly contribute to an FDA-cleared solution reinforces the value of high-quality data in driving meaningful innovation.
See More
PainReform Ltd. (PRFX) Announces Name Change, Shares Surge 27.4%
- Significant Stock Surge: PainReform Ltd. shares rose 27.4% to $1.02 in pre-market trading following the announcement of a name change and expansion into diversified healthcare and AI-driven energy platforms, indicating strong market confidence in its new strategy.
- Diversification Strategy: The name change reflects the company's strategic shift towards healthcare and energy sectors, aiming to attract more investors and enhance brand recognition, thereby strengthening its competitive position in the market.
- Market Movements: In pre-market trading, Acco Group Holdings saw a staggering 219.4% increase, highlighting strong investor interest in high-growth potential companies, which may influence perceptions of other related stocks.
- Industry Trends: As the integration of healthcare and energy sectors accelerates, PainReform's strategic adjustments align with industry developments and could provide the company with long-term growth opportunities.
See More
Insider Buying Update for Friday, November 28: EXEL, ONMD
Exelixis Insider Purchase: Director David Edward Johnson bought 27,532 shares of EXEL at $43.12 each, totaling $1.19M, marking his first purchase in a year. EXEL's stock was up about 0.7% on Friday, reaching a high of $44.85.
OneMedNet Insider Purchase: Director Thomas Kosasa purchased 1,879,871 shares of OneMedNet for $1.05M at $0.56 each. The stock surged 45.1% on Friday, with Kosasa's investment up approximately 301.2% at its peak, reaching $2.24.
See More
OneMedNet Unveils Redesigned Data Platform, Enhancing Research Efficiency
- Platform Redesign: OneMedNet showcased its completely redesigned data exploration and cohort-building platform at ISPOR Europe, receiving strong validation from customers and prospects. Built on Palantir Foundry and AIP, the platform reduces research time from days to minutes, significantly enhancing team efficiency.
- Network Expansion: The iRWD™ network now spans over 2,130 provider sites, covering 47 million unique patients and more than 186 million clinical exams and images. This extensive data infrastructure supports pharmaceutical and healthcare technology firms, driving industry innovation.
- AI-Driven Search Capabilities: The new platform features AI-driven natural language search for complex discovery tasks, providing real-time availability and longitudinal insights. This advancement allows clients to assess cohort feasibility faster, addressing market demands for rapid response.
- Recurring Revenue Growth: The platform's tight integration with subscription workflows supports OneMedNet's recurring revenue growth strategy. CEO Aaron Green emphasized that this transformation meets market needs, enabling clients to determine cohort feasibility in minutes, thereby enhancing the company's competitive edge.
See More
Rapid Growth in Cardiac AI Diagnostics Market
- Market Surge: The global medical imaging market reached $45.5 billion in 2026, indicating a significant shift towards AI-native precision, particularly due to the rising demand for heart monitoring in cancer treatments.
- Rise of Cardiac AI Diagnostics: The cardiac AI diagnostics sector hit $2.22 billion in 2026, driven by the urgent need for continuous imaging to monitor heart dysfunction, enhancing the company's competitive edge in the medical technology market.
- Strategic Partnership Enhances Value: Ventripoint's collaboration with Summit Sciences to develop ROI models illustrates how hospitals can achieve cost savings through technological improvements, further solidifying its market position in cardiac care.
- Executive Appointment Fuels Growth: The appointment of David Swetlow as CFO, with extensive experience in medical technology, is expected to accelerate market adoption and revenue growth, driving the execution of the company's commercial strategy.
See More
Rapid Growth in Cardiac AI Diagnostics Market
- Market Size Surge: The global medical imaging market reached $45.5 billion in 2026, indicating a significant shift towards AI-driven precision, with the cardiac AI diagnostics sector hitting $2.22 billion, reflecting a critical demand for continuous imaging.
- Technological Innovation: VentriPoint Diagnostics is transforming standard 2D ultrasound images into MRI-level 3D heart models, significantly reducing costs and complexity, which is expected to drive rapid growth in its subscription business.
- Surge in Investment Demand: The company recently doubled its private placement from $500,000 to $1 million, with funds allocated for commercialization and market expansion, showcasing strong investor confidence in its technology and market potential.
- Strategic Partnership: VentriPoint's collaboration with Summit Sciences to develop ROI models aims to demonstrate the economic value of its technology to hospitals, further solidifying its market position in medical imaging.
See More
OneMedNet (ONMD) Aids mlHealth in FDA Approval of AI BrainCT Software
- FDA Approval Milestone: OneMedNet partnered with mlHealth 360 to secure FDA clearance for Scaida BrainCT-ICH, an AI software that detects intracranial hemorrhage from head CT scans in approximately 5.97 seconds, significantly enhancing clinical decision-making in acute care.
- Critical Data Support: OneMedNet's regulatory-grade Real-World Data, encompassing electronic medical records, diagnostic imaging, and clinical reports, played a pivotal role in model development, validation, and regulatory submission, underscoring the importance of high-quality data in accelerating innovation.
- Market Performance Review: Over the past year, ONMD's stock traded between $0.30 and $4.22, with a nearly 7% increase to $0.92, reflecting market recognition of its innovative capabilities.
- CEO Insights: OneMedNet's CEO Aaron Green stated that seeing the company's Real-World Data directly contribute to an FDA-cleared solution reinforces the value of high-quality data in driving meaningful innovation.
See More
PainReform Ltd. (PRFX) Announces Name Change, Shares Surge 27.4%
- Significant Stock Surge: PainReform Ltd. shares rose 27.4% to $1.02 in pre-market trading following the announcement of a name change and expansion into diversified healthcare and AI-driven energy platforms, indicating strong market confidence in its new strategy.
- Diversification Strategy: The name change reflects the company's strategic shift towards healthcare and energy sectors, aiming to attract more investors and enhance brand recognition, thereby strengthening its competitive position in the market.
- Market Movements: In pre-market trading, Acco Group Holdings saw a staggering 219.4% increase, highlighting strong investor interest in high-growth potential companies, which may influence perceptions of other related stocks.
- Industry Trends: As the integration of healthcare and energy sectors accelerates, PainReform's strategic adjustments align with industry developments and could provide the company with long-term growth opportunities.
See More
Insider Buying Update for Friday, November 28: EXEL, ONMD
Exelixis Insider Purchase: Director David Edward Johnson bought 27,532 shares of EXEL at $43.12 each, totaling $1.19M, marking his first purchase in a year. EXEL's stock was up about 0.7% on Friday, reaching a high of $44.85.
OneMedNet Insider Purchase: Director Thomas Kosasa purchased 1,879,871 shares of OneMedNet for $1.05M at $0.56 each. The stock surged 45.1% on Friday, with Kosasa's investment up approximately 301.2% at its peak, reaching $2.24.
See More
OneMedNet Unveils Redesigned Data Platform, Enhancing Research Efficiency
- Platform Redesign: OneMedNet showcased its completely redesigned data exploration and cohort-building platform at ISPOR Europe, receiving strong validation from customers and prospects. Built on Palantir Foundry and AIP, the platform reduces research time from days to minutes, significantly enhancing team efficiency.
- Network Expansion: The iRWD™ network now spans over 2,130 provider sites, covering 47 million unique patients and more than 186 million clinical exams and images. This extensive data infrastructure supports pharmaceutical and healthcare technology firms, driving industry innovation.
- AI-Driven Search Capabilities: The new platform features AI-driven natural language search for complex discovery tasks, providing real-time availability and longitudinal insights. This advancement allows clients to assess cohort feasibility faster, addressing market demands for rapid response.
- Recurring Revenue Growth: The platform's tight integration with subscription workflows supports OneMedNet's recurring revenue growth strategy. CEO Aaron Green emphasized that this transformation meets market needs, enabling clients to determine cohort feasibility in minutes, thereby enhancing the company's competitive edge.
See More
